US EditionBreakthrough personalized vaccine shows promising results in kidney cancer trial
- All nine patients in a clinical trial for stage III or IV clear cell renal cell carcinoma generated a successful anti-cancer immune response after receiving a personalized cancer vaccine, as reported by Dana-Farber Cancer Institute.
- At the median follow-up of 34.7 months, all patients remained cancer-free, according to the results published in Nature.
- The vaccine induced an immune response within three weeks, with T cells increasing by a mean of 166-fold and remaining at high levels for up to three years.
- Larger clinical trials are needed to confirm the vaccine's effectiveness and explore its full potential, as stated by Toni Choueiri, MD.
24 Articles
24 Articles
New kidney cancer vaccine puts 9 advance-stage patients into remission
Researchers developed a personalized vaccine that triggered a strong immune response in nine patients with advanced kidney cancer during an early-stage clinical trial, keeping the disease in remission for at least three years.
Personalized vaccines halt kidney cancer after encouraging phase 1 trial
In a remarkable advancement for cancer immunotherapy, researchers at Dana-Farber Cancer Institute have developed personalized vaccines that successfully triggered immune responses in all nine patients with high-risk kidney cancer. The post Personalized vaccines halt kidney cancer after encouraging phase 1 trial appeared first on Study Finds.
Results from a phase 1 clinical trial indicate that patients with kidney cancer at the high risk of recurrence generated a satisfactory “immune response” against the cancer.
Breakthrough personalized vaccine shows promising results in kidney cancer trial
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
The usual treatment for people with advanced kidney cancer is surgery to remove the tumor. Next, immunotherapy is applied, a type of treatment that helps the immune system attack the cancer, to reduce the risk of relapse. With this therapeutic combination, one third recover, but the rest suffer recurrences and are left with few options. This Wednesday, Nature magazine publishes the findings of a pilot study conducted with nine patients with kidn…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
